Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-stage, Randomized, Double-blind, Dose Ranging Phase 2 Trial in Healthy Adult Participants to Investigate Optimal Dose and Dosing Regimen, and to Evaluate Safety and Immunogenicity of the Recombinant MVA-BN-WEV Vaccine

NCT06899802 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT06899802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06899802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-stage, Randomized, Double-blind, Dose Ranging Phase 2 Trial in Healthy Adult Participants to Investigate Optimal Dose and Dosing Regimen, and to Evaluate Safety and Immunogenicity of the Recombinant MVA-BN-WEV Vaccine
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 10, 2025
Completion date
March 31, 2027
Enrollment
411 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

encephalitis